← All trials
NCT07083375
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2025
- Primary completion
- Jun 1, 2027
- Completion date
- Jun 1, 2027
- First posted
- Jul 24, 2025
- Last posted
- Jul 24, 2025
- Enrollment
- 56
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Hebei UniversityCollaborator
- Chinese Academy of Medical SciencesSponsor investigator
- Wuhan UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Peking UniversityCollaborator
- Peking UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.